Open AccessPrescribing and deprescribing in chronic kidney disease
Author(s) -
JoAnne ManskiNankervis,
Rita McMorrow,
Craig Nelson,
Shilpanjali Jesudason,
Janet K. Sluggett
Publication year - 2021
Publication title -
australian journal of general practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 42
eISSN - 2208-794X
pISSN - 2208-7958
DOI - 10.31128/ajgp-11-20-5752
Subject(s) - deprescribing , medicine , kidney disease , intensive care medicine , polypharmacy
Chronic kidney disease (CKD) rarely occurs in isolation; multimorbidity is the norm. As a result, polypharmacy is common in people with CKD. Some medications are indicated to reduce the risk of cardiovascular disease and progression of CKD. In contrast, some medications may require dose reduction or cessation as a result of advancing stages of CKD.